Autres langues EBOS Group Limited

Actions

EBO

NZEBOE0001S6

Produits pharmaceutiques

Cours en clôture New Zealand S.E. 14/08/2026			Varia. 5j.	Varia. 1 janv.
21,23 ^NZD	-2,75 %		-2,35 %	-23,14 %

14/08	NZX : les plus fortes baisses	MT
10/08	Point de mi-séance à la NZX : progression des technologies de santé, repli de l'électronique	MT

Autres langues

14/08	NZX Biggest Losers
10/08	NZX Midday Sector Update: Health Technology Advances, Electronic Technology Declines
12/06	New Zealand Shares Rise; Fonterra Co-operative Group Appoints Elisa Giusti Chief Growth, Strategy Officer
12/06	NZX Biggest Gainers
12/06	ASX Preview: Australian Shares Set to Rise; Bathurst Resources Says New Zealand High Court Dismisses Talley's Group Derivative Lawsuit Bid
12/06	Ebos Group's Proposed Acquisition of Paringa Pet Foods Under Phase One ACCC Review
03/06	Ebos Group Underperforms in Last 12 Months After Contract Loss, Management Shakeup, Jarden Says
22/05	NZX Biggest Gainers
06/05	EBOS : Investor Day Presentation
22/04	EBOS Group Lowers Fiscal 2026 EBITDA Guidance on Higher Energy Costs
27/03	EBOS Group Issues Nearly 2 Million Shares Under Dividend Reinvestment Plan
27/03	NZX Biggest Gainers
23/03	EBOS Group Limited(ASX:EBO) dropped from S&P/ASX 200 Index
13/03	Advent International and Blackstone Reportedly in Race to Buy Real Pet Food Group
09/03	Predictive Discovery, SRG Global, Vulcan Energy Resources to be Included in S&P/ASX 200 Index
25/02	EBOS Group Limited acquired an unknown majority stake in MediAdvice Pty Ltd.
25/02	New Zealand Shares End Slightly Lower; Meridian Energy Swings to Fiscal H1 Profit, Posts Lower Revenue
24/02	EBOS : 2026 Interim Report
24/02	EBOS Group Limited Reports Earnings Results for the Half Year Ended December 31, 2025
24/02	EBOS Group Posts Lower Fiscal H1 Underlying Earnings, Higher Revenue; Reaffirms Fiscal 2026 Outlook
24/02	EBOS : Interim Shareholders Report 2026
24/02	EBOS Group Limited Declares Ordinary Actual Interim Dividend for the Six Months Ended December 31, 2025, Payable on March 27 2026
24/02	Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect
03/02	ASX Biggest Losers
28/01	NZX Midday Sector Update: Non-Energy Minerals Soar, Health Technology Struggles